C
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
Price:
85.6
TWD
-6.75%
Market Closed
Market Cap:
NT$133B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
C
|
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
|
TW |
|
Growthpoint Properties Australia Ltd
ASX:GOZ
|
AU |
|
A
|
Ability Enterprise Co Ltd
TWSE:2374
|
TW |
|
Broedrene A & O Johansen A/S
CSE:AOJ B
|
DK |
|
Y
|
YY Group Holding Ltd
NASDAQ:YYGH
|
SG |
|
SK Hynix Inc
KRX:000660
|
KR |
Income Statement
Earnings Waterfall
Caliway Biopharmaceuticals Co Ltd
Caliway Biopharmaceuticals Co Ltd
Income Statement
Caliway Biopharmaceuticals Co Ltd
Caliway Biopharmaceuticals Co Ltd
Currency: TWD
| Dec-2022 | Jun-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||
| Interest Expense |
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
13
N/A
|
28
+118%
|
39
+39%
|
43
+11%
|
36
-17%
|
59
+65%
|
44
-25%
|
40
-9%
|
45
+11%
|
35
-22%
|
38
+9%
|
|
| Gross Profit | ||||||||||||
| Cost of Revenue |
(3)
|
(8)
|
(11)
|
(13)
|
(10)
|
(18)
|
(14)
|
(12)
|
(14)
|
(11)
|
(12)
|
|
| Gross Profit |
10
N/A
|
20
+106%
|
27
+39%
|
30
+11%
|
5
-83%
|
21
+305%
|
31
+45%
|
28
-9%
|
31
+10%
|
24
-22%
|
27
+9%
|
|
| Operating Income | ||||||||||||
| Operating Expenses |
(329)
|
(488)
|
(541)
|
(785)
|
(700)
|
(868)
|
(748)
|
(731)
|
(697)
|
(740)
|
(734)
|
|
| Selling, General & Administrative |
(34)
|
(32)
|
(37)
|
(48)
|
(56)
|
(92)
|
(98)
|
(112)
|
(162)
|
(92)
|
(83)
|
|
| Research & Development |
(295)
|
(455)
|
(504)
|
0
|
(175)
|
(309)
|
(650)
|
(619)
|
(536)
|
(647)
|
(651)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
(736)
|
(468)
|
(468)
|
0
|
0
|
0
|
0
|
0
|
|
| Operating Income |
(320)
N/A
|
(468)
-46%
|
(513)
-10%
|
(754)
-47%
|
(675)
+10%
|
(828)
-23%
|
(717)
+13%
|
(704)
+2%
|
(667)
+5%
|
(716)
-7%
|
(707)
+1%
|
|
| Pre-Tax Income | ||||||||||||
| Interest Income Expense |
19
|
24
|
16
|
0
|
18
|
22
|
113
|
144
|
35
|
225
|
356
|
|
| Gain/Loss on Disposition of Assets |
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
15
|
15
|
9
|
48
|
35
|
46
|
16
|
14
|
14
|
2
|
(0)
|
|
| Pre-Tax Income |
(286)
N/A
|
(429)
-50%
|
(488)
-14%
|
(706)
-45%
|
(622)
+12%
|
(760)
-22%
|
(589)
+23%
|
(547)
+7%
|
(618)
-13%
|
(488)
+21%
|
(352)
+28%
|
|
| Net Income | ||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(286)
|
(429)
|
(488)
|
(706)
|
(622)
|
(760)
|
(589)
|
(547)
|
(618)
|
(488)
|
(352)
|
|
| Net Income (Common) |
(286)
N/A
|
(429)
-50%
|
(488)
-14%
|
(706)
-45%
|
(622)
+12%
|
(760)
-22%
|
(589)
+23%
|
(547)
+7%
|
(618)
-13%
|
(488)
+21%
|
(352)
+28%
|
|
| EPS (Diluted) |
-4.64
N/A
|
-6.95
-50%
|
-0.39
+94%
|
-5.08
-1 203%
|
-4.47
+12%
|
-0.54
+88%
|
-0.41
+24%
|
-0.35
+15%
|
-0.42
-20%
|
-0.32
+24%
|
-0.23
+28%
|
|
Switch to:
Switch to:
See Also
Discover More
